AI Tokens
Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Microsoft Excel

Long-term Activity Ratios (Summary)

Thermo Fisher Scientific Inc., long-term (investment) activity ratios (quarterly data)

Microsoft Excel
Sep 26, 2026 Jun 27, 2026 Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Net fixed asset turnover 4.48 4.31 4.24 4.22 4.30 4.48 4.60 4.61 4.50 4.56 4.56 4.54 4.74 4.68 4.68 4.84 5.12 5.02 4.87
Total asset turnover 0.41 0.41 0.40 0.40 0.42 0.43 0.43 0.44 0.42 0.43 0.44 0.43 0.45 0.46 0.46 0.46 0.49 0.47 0.44
Equity turnover 0.86 0.88 0.87 0.83 0.86 0.86 0.87 0.86 0.86 0.89 0.93 0.92 0.96 0.99 1.04 1.02 1.01 1.01 1.00

Based on: 10-Q (reporting date: 2026-09-26), 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).


The analysis of long-term activity ratios reveals a general decline in asset utilization efficiency from 2022 through late 2026, with a slight recovery observed in the final quarters of the period.

Net Fixed Asset Turnover
This ratio peaked at 5.12 in October 2022 before entering a prolonged downward trend. A consistent decline is observed through 2023 and 2024, reaching a minimum of 4.22 by December 2025. However, the final three quarters show a recovery trend, with the ratio climbing back to 4.48 by September 2026, suggesting an improvement in the efficiency of fixed asset utilization toward the end of the period.
Total Asset Turnover
Total asset efficiency remained relatively low and exhibited a gradual contraction. After reaching a high of 0.49 in October 2022, the ratio fluctuated with a downward bias, spending much of 2024 and 2025 between 0.40 and 0.43. The period concluded with the ratio stabilizing at 0.41, indicating a slight overall reduction in the revenue generated per unit of total assets.
Equity Turnover
Equity utilization showed a more pronounced decline compared to total asset turnover. The ratio initially hovered around 1.00 and peaked at 1.04 in April 2023, but subsequently entered a steady decline. It reached a trough of 0.83 in December 2025 before recovering slightly to 0.86 by September 2026. This pattern indicates that the company's ability to generate sales from shareholders' equity diminished over the observed timeframe.

Overall, the synchronized decline across all three metrics suggests that the growth in the asset base and equity outpaced revenue growth for a significant portion of the analyzed period. The modest upturn in turnover ratios in 2026 indicates a potential stabilization in operational efficiency.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Net Fixed Asset Turnover

Thermo Fisher Scientific Inc., net fixed asset turnover calculation (quarterly data)

Microsoft Excel
Sep 26, 2026 Jun 27, 2026 Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data (US$ in millions)
Revenues 12,137 11,994 11,005 12,215 11,122 10,855 10,364 11,395 10,598 10,541 10,345 10,886 10,574 10,687 10,710 11,450 10,677 10,970 11,818
Property, plant and equipment, net 10,577 10,755 10,658 10,565 10,177 9,635 9,331 9,306 9,412 9,282 9,324 9,448 9,167 9,292 9,354 9,280 8,628 8,529 8,448
Long-term Activity Ratio
Net fixed asset turnover1 4.48 4.31 4.24 4.22 4.30 4.48 4.60 4.61 4.50 4.56 4.56 4.54 4.74 4.68 4.68 4.84 5.12 5.02 4.87
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc. 11.11 11.11 11.05 10.87 10.88 11.04 10.95 10.97 10.80 10.95 10.92 10.89 11.18 11.33 11.51 11.76 11.82 11.57 11.18
Amgen Inc. 4.17 4.24 4.32 4.44 4.78 4.89 4.91 4.89 5.06 4.85 4.70 4.53 4.61 4.58 4.56 4.57 4.73 4.77 4.75
Bristol-Myers Squibb Co. 6.28 6.31 6.33 6.39 6.54 6.47 6.60 6.77 6.87 6.79 6.75 6.77 6.93 7.11 7.30 7.38 7.74 7.90 7.77
Danaher Corp. 4.44 4.31 4.53 4.44 4.51 4.52 4.66 4.78 4.90 5.08 5.20 5.25 6.01 6.68 7.31 7.96 8.40 8.12 7.94
Eli Lilly & Co. 2.69 2.72 2.72 2.64 2.66 2.59 2.65 2.63 2.53 2.62 2.64 2.64 2.70 2.62 2.63 2.81 3.14 3.18 3.22
Gilead Sciences Inc. 5.17 5.11 5.19 5.16 5.19 5.26 5.27 5.28 5.22 5.17 5.13 5.07 4.88 4.91 4.88 4.93 5.01 5.13 5.18
Johnson & Johnson 4.12 4.15 4.14 4.07 4.13 4.13 4.28 4.33 4.28 4.38 4.36 4.28 4.65 4.37 4.58 4.79 5.29 5.21 5.07
Merck & Co. Inc. 2.60 2.59 2.59 2.57 2.51 2.52 2.58 2.70 2.69 2.69 2.66 2.61 2.63 2.62 2.66 2.77 2.89 2.85 2.73
Pfizer Inc. 3.34 3.35 3.26 3.24 3.33 3.40 3.40 3.46 3.26 2.97 2.98 3.14 3.88 4.48 5.46 6.17 6.47 6.64 6.12
Regeneron Pharmaceuticals Inc. 2.95 2.85 2.83 2.80 2.85 2.94 3.00 3.09 3.12 3.13 3.10 3.16 3.27 3.23 3.19 3.23 3.70 3.91 4.64
Vertex Pharmaceuticals Inc. 7.57 7.56 7.60 7.89 8.23 8.55 8.57 8.98 9.51 8.61 8.68 8.51 8.59 8.47 8.28 8.06 7.78 7.59 7.18

Based on: 10-Q (reporting date: 2026-09-26), 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q3 2026 Calculation
Net fixed asset turnover = (RevenuesQ3 2026 + RevenuesQ2 2026 + RevenuesQ1 2026 + RevenuesQ4 2025) ÷ Property, plant and equipment, net
= (12,137 + 11,994 + 11,005 + 12,215) ÷ 10,577 = 4.48

2 Click competitor name to see calculations.


The net fixed asset turnover ratio exhibits a general downward trajectory over the analyzed period, characterized by a peak in late 2022 followed by a gradual decline and a slight recovery toward the end of 2026. This trend suggests a shift in the relationship between the company's investment in long-term physical assets and its ability to generate revenue from those assets.

Revenue Performance
Revenues remained relatively stable for a significant portion of the period, fluctuating primarily between $10.3 billion and $11.4 billion. A growth phase is observable starting in late 2025, with quarterly revenues peaking at $12.2 billion in December 2025 and maintaining levels above $11.9 billion through September 2026.
Fixed Asset Expansion
There is a consistent upward trend in net property, plant, and equipment. Assets grew from $8.4 billion in April 2022 to a peak of $10.7 billion in June 2026. This steady increase indicates a sustained commitment to capital expenditure and the expansion of the company's productive capacity.
Asset Utilization Efficiency
The net fixed asset turnover ratio reached a high of 5.12 in October 2022 but declined steadily to a low of 4.22 by December 2024. This decline is attributed to the fact that the growth in the net fixed asset base outpaced the growth in revenue, resulting in lower revenue generation per dollar of fixed assets.
Recent Trend Analysis
A moderate recovery in efficiency is observed throughout 2026, with the ratio rising from 4.24 in March to 4.48 in September. This improvement aligns with the increase in quarterly revenues, suggesting that the capacity added through previous capital investments began to translate into higher top-line growth, thereby improving asset productivity.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Total Asset Turnover

Thermo Fisher Scientific Inc., total asset turnover calculation (quarterly data)

Microsoft Excel
Sep 26, 2026 Jun 27, 2026 Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data (US$ in millions)
Revenues 12,137 11,994 11,005 12,215 11,122 10,855 10,364 11,395 10,598 10,541 10,345 10,886 10,574 10,687 10,710 11,450 10,677 10,970 11,818
Total assets 114,233 113,174 113,281 110,343 103,020 101,230 99,041 97,321 100,364 98,496 97,095 98,726 97,057 94,105 94,658 97,154 90,536 90,579 92,747
Long-term Activity Ratio
Total asset turnover1 0.41 0.41 0.40 0.40 0.42 0.43 0.43 0.44 0.42 0.43 0.44 0.43 0.45 0.46 0.46 0.46 0.49 0.47 0.44
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc. 0.45 0.48 0.46 0.46 0.45 0.43 0.42 0.42 0.39 0.39 0.37 0.40 0.40 0.41 0.42 0.42 0.41 0.40 0.40
Amgen Inc. 0.39 0.38 0.38 0.39 0.38 0.38 0.37 0.35 0.34 0.32 0.30 0.28 0.28 0.28 0.28 0.38 0.38 0.41 0.41
Bristol-Myers Squibb Co. 0.56 0.56 0.56 0.54 0.50 0.50 0.52 0.52 0.51 0.49 0.46 0.47 0.49 0.48 0.49 0.48 0.48 0.47 0.46
Danaher Corp. 0.27 0.27 0.30 0.29 0.30 0.29 0.30 0.31 0.29 0.30 0.28 0.28 0.29 0.33 0.35 0.37 0.39 0.38 0.36
Eli Lilly & Co. 0.58 0.56 0.62 0.58 0.52 0.53 0.55 0.57 0.54 0.54 0.56 0.53 0.55 0.54 0.52 0.58 0.62 0.62 0.62
Gilead Sciences Inc. 0.60 0.60 0.52 0.49 0.49 0.52 0.51 0.48 0.52 0.52 0.48 0.43 0.44 0.44 0.43 0.43 0.43 0.43 0.43
Johnson & Johnson 0.50 0.49 0.48 0.47 0.48 0.47 0.46 0.49 0.49 0.48 0.50 0.51 0.53 0.47 0.47 0.51 0.55 0.54 0.53
Merck & Co. Inc. 0.51 0.51 0.51 0.47 0.50 0.54 0.56 0.55 0.54 0.55 0.58 0.56 0.56 0.56 0.54 0.54 0.55 0.53 0.51
Pfizer Inc. 0.31 0.32 0.30 0.30 0.30 0.31 0.30 0.30 0.28 0.26 0.25 0.26 0.32 0.36 0.48 0.51 0.51 0.52 0.50
Regeneron Pharmaceuticals Inc. 0.38 0.37 0.37 0.35 0.35 0.37 0.38 0.38 0.37 0.37 0.38 0.40 0.41 0.41 0.41 0.42 0.50 0.52 0.63
Vertex Pharmaceuticals Inc. 0.40 0.46 0.46 0.47 0.47 0.48 0.49 0.49 0.48 0.51 0.43 0.43 0.44 0.47 0.49 0.49 0.52 0.54 0.56

Based on: 10-Q (reporting date: 2026-09-26), 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q3 2026 Calculation
Total asset turnover = (RevenuesQ3 2026 + RevenuesQ2 2026 + RevenuesQ1 2026 + RevenuesQ4 2025) ÷ Total assets
= (12,137 + 11,994 + 11,005 + 12,215) ÷ 114,233 = 0.41

2 Click competitor name to see calculations.


The analysis of total asset turnover reveals a general decline in asset utilization efficiency from April 2022 through September 2026. Although the ratio remained relatively stable between 0.43 and 0.46 for a significant portion of 2023, a more pronounced downward trend emerged starting in mid-2024, culminating in a period of stagnation at approximately 0.40 to 0.41 through 2026.

Revenue Trends
Revenues exhibited moderate volatility throughout the period, fluctuating between a low of 10,345 million USD in March 2024 and a peak of 12,215 million USD in December 2025. While there is evidence of growth in the final year of the sequence, the revenue trajectory remained inconsistent compared to the steady growth of the asset base.
Total Asset Growth
A consistent upward trend in total assets is observed, with the value increasing from 92,747 million USD in April 2022 to 114,233 million USD by September 2026. This expansion indicates a significant increase in the company's investment in its balance sheet, which serves as the denominator for the turnover ratio.
Asset Turnover Interpretation
The decline in the total asset turnover ratio from a peak of 0.49 in October 2022 to 0.41 in September 2026 indicates that the asset base grew at a faster rate than the revenues generated. This divergence suggests a decrease in the immediate productivity of the company's investments, as the growth in total assets was not matched by a proportional increase in top-line revenue.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Equity Turnover

Thermo Fisher Scientific Inc., equity turnover calculation (quarterly data)

Microsoft Excel
Sep 26, 2026 Jun 27, 2026 Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data (US$ in millions)
Revenues 12,137 11,994 11,005 12,215 11,122 10,855 10,364 11,395 10,598 10,541 10,345 10,886 10,574 10,687 10,710 11,450 10,677 10,970 11,818
Total Thermo Fisher Scientific Inc. shareholders’ equity 54,761 52,679 51,934 53,407 51,018 50,512 49,390 49,584 48,992 47,432 45,516 46,735 45,328 43,752 42,257 43,978 43,549 42,293 40,956
Long-term Activity Ratio
Equity turnover1 0.86 0.88 0.87 0.83 0.86 0.86 0.87 0.86 0.86 0.89 0.93 0.92 0.96 0.99 1.04 1.02 1.01 1.01 1.00
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc. — — — — — — 40.40 16.94 9.21 8.11 6.79 5.24 4.56 4.35 4.27 3.36 3.62 3.91 3.48
Amgen Inc. 2.58 3.10 3.86 4.06 3.59 4.51 5.28 5.45 4.14 4.99 5.61 4.32 3.35 3.73 4.66 6.77 6.71 10.17 26.68
Bristol-Myers Squibb Co. 2.14 2.20 2.42 2.61 2.59 2.74 2.74 2.96 2.77 2.73 2.76 1.53 1.55 1.41 1.44 1.49 1.43 1.45 1.49
Danaher Corp. 0.48 0.48 0.47 0.47 0.48 0.46 0.47 0.48 0.46 0.47 0.44 0.45 0.49 0.54 0.58 0.63 0.67 0.66 0.65
Eli Lilly & Co. 2.15 2.35 2.32 2.46 2.50 2.91 3.11 3.17 2.87 2.87 2.80 3.17 2.86 2.67 2.47 2.68 2.90 3.40 3.14
Gilead Sciences Inc. 2.36 2.52 1.24 1.27 1.33 1.46 1.49 1.48 1.52 1.51 1.56 1.18 1.22 1.28 1.27 1.27 1.27 1.34 1.37
Johnson & Johnson 1.22 1.15 1.19 1.16 1.16 1.15 1.14 1.24 1.25 1.21 1.22 1.24 1.23 1.20 1.30 1.24 1.29 1.25 1.27
Merck & Co. Inc. 1.50 1.59 1.43 1.24 1.24 1.30 1.32 1.39 1.42 1.43 1.52 1.60 1.44 1.51 1.24 1.29 1.33 1.32 1.32
Pfizer Inc. 0.71 0.75 0.70 0.72 0.68 0.72 0.69 0.72 0.65 0.64 0.61 0.67 0.71 0.79 0.92 1.05 1.08 1.16 1.12
Regeneron Pharmaceuticals Inc. 0.50 0.49 0.47 0.46 0.46 0.47 0.48 0.48 0.47 0.48 0.49 0.51 0.53 0.53 0.53 0.54 0.64 0.69 0.83
Vertex Pharmaceuticals Inc. 0.62 0.62 0.63 0.64 0.68 0.66 0.67 0.67 0.68 0.70 0.55 0.56 0.58 0.61 0.64 0.64 0.67 0.70 0.73

Based on: 10-Q (reporting date: 2026-09-26), 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q3 2026 Calculation
Equity turnover = (RevenuesQ3 2026 + RevenuesQ2 2026 + RevenuesQ1 2026 + RevenuesQ4 2025) ÷ Total Thermo Fisher Scientific Inc. shareholders’ equity
= (12,137 + 11,994 + 11,005 + 12,215) ÷ 54,761 = 0.86

2 Click competitor name to see calculations.


The financial analysis reveals a divergent trajectory between revenue generation and the growth of shareholders' equity, resulting in a gradual decline in equity turnover efficiency over the observed period.

Revenue Performance
Revenues exhibited a period of volatility, starting at 11,818 million USD in April 2022 and reaching a trough of 10,345 million USD by March 2024. Following this low point, a recovery phase is observed, with revenues trending upward to reach 12,137 million USD by September 2026. This indicates a cyclical pattern of contraction followed by a steady expansion in top-line performance.
Shareholders' Equity Expansion
Total shareholders' equity demonstrated a consistent and sustained upward trend. From a base of 40,956 million USD in April 2022, equity grew to 54,761 million USD by September 2026. This steady accumulation of equity indicates a strengthening of the balance sheet and a continuous increase in the company's internal funding base.
Equity Turnover Dynamics
The equity turnover ratio experienced a progressive contraction, shifting from a peak of 1.04 in April 2023 to a range between 0.83 and 0.88 throughout 2025 and 2026. The initial stability near the 1.00 ratio during 2022 transitioned into a downward trend as the growth in shareholders' equity outpaced the growth in revenues. This suggests a decrease in the efficiency with which the equity base is utilized to generate sales.
Correlation Analysis
The decline in equity turnover is primarily driven by the compounding effect of rising equity levels against relatively stagnant or slowly recovering revenues. While the company has successfully expanded its capital base, the capacity of this capital to drive proportional revenue growth diminished over the analyzed timeframe, leading to a lower overall turnover rate by the end of the period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?